WO2012090218A1 - Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases - Google Patents
Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases Download PDFInfo
- Publication number
- WO2012090218A1 WO2012090218A1 PCT/IN2011/000867 IN2011000867W WO2012090218A1 WO 2012090218 A1 WO2012090218 A1 WO 2012090218A1 IN 2011000867 W IN2011000867 W IN 2011000867W WO 2012090218 A1 WO2012090218 A1 WO 2012090218A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- combination
- paracetamol
- concentration
- caffeine
- synergistic effects
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 31
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 229960005489 paracetamol Drugs 0.000 title claims abstract description 25
- 201000010099 disease Diseases 0.000 title claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 8
- 230000002195 synergetic effect Effects 0.000 title claims description 12
- 230000000694 effects Effects 0.000 title claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 38
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960001948 caffeine Drugs 0.000 claims abstract description 19
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 19
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940080308 racemethionine Drugs 0.000 claims abstract description 15
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims abstract description 14
- 229960001802 phenylephrine Drugs 0.000 claims abstract description 14
- 208000002193 Pain Diseases 0.000 claims abstract description 12
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 12
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 11
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims abstract description 11
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims abstract description 11
- 230000005764 inhibitory process Effects 0.000 claims abstract description 11
- 230000036407 pain Effects 0.000 claims abstract description 11
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000001387 anti-histamine Effects 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 9
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims abstract description 9
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims abstract description 9
- 230000007815 allergy Effects 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 208000026935 allergic disease Diseases 0.000 claims abstract description 8
- 230000002443 hepatoprotective effect Effects 0.000 claims abstract description 7
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 6
- 206010037660 Pyrexia Diseases 0.000 claims abstract description 6
- 201000007930 alcohol dependence Diseases 0.000 claims abstract description 6
- 239000000850 decongestant Substances 0.000 claims abstract description 6
- 208000019423 liver disease Diseases 0.000 claims abstract description 6
- 206010011224 Cough Diseases 0.000 claims abstract description 5
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 5
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 5
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000005864 Sulphur Substances 0.000 claims abstract description 4
- 210000005229 liver cell Anatomy 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 3
- 208000018565 Hemochromatosis Diseases 0.000 claims abstract description 3
- 208000008589 Obesity Diseases 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 3
- 230000007882 cirrhosis Effects 0.000 claims abstract description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 3
- 238000001784 detoxification Methods 0.000 claims abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 3
- 235000020824 obesity Nutrition 0.000 claims abstract description 3
- 231100000748 severe hepatic injury Toxicity 0.000 claims abstract description 3
- 206010019851 Hepatotoxicity Diseases 0.000 claims abstract 2
- 231100000304 hepatotoxicity Toxicity 0.000 claims abstract 2
- 230000007686 hepatotoxicity Effects 0.000 claims abstract 2
- 231100000419 toxicity Toxicity 0.000 claims abstract 2
- 230000001988 toxicity Effects 0.000 claims abstract 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 14
- 108010024636 Glutathione Proteins 0.000 claims description 7
- 229960003180 glutathione Drugs 0.000 claims description 7
- 230000007246 mechanism Effects 0.000 claims description 7
- 230000001624 sedative effect Effects 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims description 3
- 210000003494 hepatocyte Anatomy 0.000 claims description 3
- 230000003908 liver function Effects 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 206010053567 Coagulopathies Diseases 0.000 claims description 2
- 230000035602 clotting Effects 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 230000001882 diuretic effect Effects 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- 231100000417 nephrotoxicity Toxicity 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 150000003595 thromboxanes Chemical class 0.000 claims description 2
- 230000010534 mechanism of action Effects 0.000 abstract description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 239000013543 active substance Substances 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 229960001340 histamine Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229960003291 chlorphenamine Drugs 0.000 description 4
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 229940111134 coxibs Drugs 0.000 description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000009346 Adenosine receptors Human genes 0.000 description 2
- 108050000203 Adenosine receptors Proteins 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000017455 cell-cell adhesion Effects 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 206010041232 sneezing Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 101100168274 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-3 gene Proteins 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040742 Sinus congestion Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229940037530 cough and cold preparations Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000003453 histamine agonist Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 201000004335 respiratory allergy Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Definitions
- the present invention is based on the combination of the specific compounds and their effects on various diseases.
- the invention relates to safety containers for biologically active substances, in particular cytostatic agents, said container having increased or higher fracture strength and shatterproof qualities, in addition to an uncontaminated exterior.
- the invention also relates to a method for producing said containers and to the use of a medium containing at least one polymer for decontaminating the exterior of a container that is filled with a biologically active substance, sealed and optionally labelled.
- the present invention relates to a process for producing a solid, coated pharmaceutical composition by a melt coating process.
- the process is adapted to provide a solid, coated pharmaceutical composition by melt coating, which has a fast release.
- compositions, methods, systems and kits for the controlled delivery of an active agent within a polymeric network upon the binding of a molecule that decreases the structural integrity of the polymeric network at one or more micro- or nanovacuoles are provided.
- the present invention relates to a gastric-retentive controlled release mono-matrix tablet composition, comprising: a) at least one pharmacologically active substance; b) hydrogel- forming materials consisting of polyethylene oxide and at least one component selected from poloxamers and colloidal silica; and c) a carbon dioxide-generating material.
- the composition of the present invention floats in gastric juice and can continuously release the active substance in the stomach at a constant rate for at least 2 hours.
- the present invention provides a pharmaceutical composition in the form of pellet wherein controlled release of pharmacologically active substances can be effected.
- the present invention is characterized by a pharmaceutical composition for controlled release pellets, consisting es -1 sentially of: a) one or more pharmacologically active substances; b) one or more lipids having a low-melting point of less than 70°C and existing as a solid at room temperature; c) one or more hydrophilic substances; and d) one or more water-insoluble binding agents, prepared without melting the lipids.
- composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof, the solid inner layer being sandwiched between two outer layers Bl) and B2), each outer layer comprising iii) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the form of one of a) a homopolymer having a MW of at least about 100,000 daltons, and b) a copolymer having a MW of at least about 2,000 daltons, or a mixture thereof, and iv) an active substance, which is the same as in said solid inner layer A), and layer A being different from layer B, the layered composition being coated with a coating C) that has at least one opening exposing at least one surface of said outer layer, the coating being substantially insoluble in and impermeable to fluids
- compositions including a sedating antihistamine and a stimulant, and methods of use thereof.
- the stimulant reduces the sedation caused by the antihistamine, thereby allowing potent, but sedating, antihistamines to be used effectively.
- the present invention relates to novel compounds that are useful for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies.
- This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies.
- the compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of infectious diseases.
- the subject invention concerns novel compounds that are useful as long-acting local anesthetics.
- the compounds are N-acyl derivatives of the compound known as tetracaine.
- An object of the present invention is the provisions of some features distinguish from others. These features are Pain management is qualitatively superior with paracetamol than with other NSAIDs drugs because paracetamol is considered to be the inhibition of cyclooxygenase (COX), and it is highly selective for COX-2. While it has analgesic and antipyretic properties comparable to those of aspirin or other NSAIDs,Pharmacological inhibition of COX can provide relief from the symptoms of inflammation and pain.
- COX cyclooxygenase
- the tolerability profile of paracetamol is better than conventional NSAIDs and is similar to that of coxibs (with respect to ulcer incidence) because paracetamol (acetaminophen), owing to its inhibitory action on cyclooxygenase, (sometimes) the paracetamol inhibiting cyclooxygenase predominantly in the central nervous system.
- paracetamol acts through the inhibition of the recently discovered COX-3 isoform.
- NSAIDs for example Ibuprofen, Indomethacin and Diclofenac may cause G.I. irritation and Cardiac Risk with COX2 inhibitor.
- This invention is mainly focused compounds, efficacy of compounds and combination of compounds. Which essential for treatment of a number of diseases. These are pain, antiinfilamation, hepatoprotective, fever thereof.
- the present invention discloses an efficient compound, compound combination and additional mechanism of compound which has several mechanisms for treatment of a number of diseases which can be treated from paracetamol, racemethionine, caffeine, chlorpheniramine maleate and Phenylephrine in variable quantities.
- COX-2 appears to be related to cancers and abnormal growths in the intestinal tract. COX inhibitors have been shown to reduce the occurrence of cancers and pre-cancerous growths. The inhibition of COX-2 is paramount for the anti-inflammatory and analgesic function of the selective COX-2 inhibitor celecoxib, and quite likely also for its ability to prevent the development of cancerous growth.
- the concentration of paracetamol is 500 mg/tablet and thereof.
- Mechanism of action is that makes paracetamol such an effective and useful medicine.
- Paracetamol has a highly targeted action in blocking an enzyme involved in the transmission of pain.
- Racemethionine is an important sulphur containing amino acid with multiple functions throughout the body. Its role as an antioxidant and hepatoprotector has been widely documented. It protects hepatocytes and enhances their regeneration thus improving liver function, it acts as important sulphur and methyl group donor in detoxification reactions in liver cells. Methyl group and is essential for many biochemical reactions. Methionine produces S-adenosylmethionine. (SAMe). SAMe is essential for the production of Glutathione. Racemethionine is used to make the urine more acidic. Making the urine more acidic helps to relieve skin irritation in incontinent (loss of bladder control). Racemethionine is necessary for glutathione synthesis. Glutathione plays an important role in the protection of liver cells. Glutathione (-SH) controls redox reactions and acts as an antioxidant and antitoxic substance.
- Methionine neutralizes Hypochlorous acid, a bleach-like substance that is secreted in the painful joints during conditions like rheumatoid arthritis. Thus methionine a lleviates the inflammation that is experienced as pain.Racemethionine has an important antiinflammatory
- racemethionine The concentration of racemethionine is 50 mg./tablet and thereof. Race Methionine acts as a glutathione precursor. The incorporation of methionine into tablets of paracetamol is useful for protecting against hepatic and renal toxicity.
- Free Radicals A molecule which is neutral contains pair of electrons while unpaired molecules are called free radicals.
- Oxidative stress seems to play a vital role in osteoarthritis, in the case of osteoarthritis human cartilage significantly deficient in superoxide dimutase a major free radical scavenger.
- Caffeine may also have hepatoprotective properties. Increased caffeine consumption is associated with less severe liver injury among those at high risk for liver disease, such as those with alcoholism, obesity, or hemochromatosis.
- Caffeine also increases the effectiveness of some drugs.
- Many over-the-counter headache drugs include caffeine in their formula. It is also used with ergotamine in the treatment of migraine and cluster headaches as well as to overcome the drowsiness caused by antihistamines.
- the concentration of caffeine is 15 mg. /tablet and thereof.
- Coffee is- a complex 'blend' of a vast number of different chemicals, any of which may be responsible for its reported effects on the liver.
- Midol In addition to the variable quantity of paracetamol and about the equivalent amount of caffeine in a cup of coffee Midol also contains a mild sedative (an antihistamine) and a mild diuretic.
- Adenosine is a water-soluble compound of adenine and ribose; it functions to modulate the activities of nerve cells and produces a mild sedative effect when it activates certain types of adenosine receptors.
- Caffeine competes with adenosine to bind at these receptors and counteracts the sedative effects of the adenosine. If the person stops drinking coffee, the adenosine has no competition for activating its usual receptors and may produce a sedative effect that is experienced as fatigue or drowsiness.
- Chlorpheniramine is often combined with phenylpropanolamine to form an allergy medication with both antihistamine and decongestant properties. It's suitable compound for cough and cold .it's containing codeine and chlorpheniramine. It's a first-generation alkylamine antihistamine used in the prevention of the symptoms of allergic conditions. It is also a potentiator of opioids, allowing enhanced suppression of cough, analgesia, and other effects from a given quantity of the drug by itself. In various places in the world, cough and cold preparations containing codeine and chlorpheniramine are available.
- the concentration of chlorphenamine maleate is 2 mg/tablet and thereof.
- Chlorpheniramine is a histamine HI antagonist (or more correctly, an inverse histamine agonist). It competes with histamine for the normal Hi -receptor sites on effectors cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. It binds to the histamine HI receptor. These blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Absorption well absorbed in the gastrointestinal tract. Phenylephrine
- Phenylephrine's effectiveness as a decongestant stems from its vasoconstriction of nasal blood vessels, thereby decreasing blood flow to the sinusoidal vessels, leading to decreased mucosal edema. All effective cold remedies containing phenylephrine.
- Phenylephrine is 5 mg/tablet and thereof.
- Phenylephrine relieves stuffy nose by constricting blood vessels in the nasal air passages. This reduces the flow of fluid out of the blood vessels and into the tissues of the air passages. Phenylephrine is used to treat runny or stuffy nose, sinus congestion, sneezing, itchy nose, itchy or watery eyes, sore throat, cough, headache, and pain or fever caused by allergies or the common cold.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention is based on efficacy of compounds and combination of compounds. Which essential for treatment of a number of diseases. These are pain, antiinfilamation, hepatoprotective, fever, allergy thereof. This combination has less toxicity, it has highly hepatotoxicity. The main mechanism of action of paracetamol is considered to be the inhibition of cyclooxygenase (COX) that it is highly selective for COX-2. The concentration of paracetamol is 500mg and thereof. Racemethionine is anti-oxidant nutritional supplement to treat liver diseases caused by alcoholism including cirrhosis. It acts as important sulphur and methyl group donor in detoxification reactions in liver cells. The concentration of racemethionine is 50mg and thereof. All effective cold remedies containing phenylephrine. The concentration of Phenylephrine is 5 mg/tablet and thereof. Phenylephrine to form an allergy medication with both antihistamine and decongestant properties. Chlorphenaminemaleate is suitable compound for cough and cold.chlorphenamine maleate to form an allergy medication with both antihistamine and decongestant properties. The concentration of chlorphenaminemaleate is 2 mg/tablet and thereof. Caffeine may also have hepatoprotective properties. Increased caffeine consumption is associated with less severe liver injury among those at high risk for liver disease, such as those with alcoholism, obesity, or hemochromatosis. The concentration of caffeine is 15 mg/tablet and thereof.
Description
SYNERGISTIC EFFECTS OF THE COMBINATION OF THE SPECIFIC COMPOUNDS WITH PARACETAMOL AND THEffi EFFECTS ON VARIOUS DISEASES
FIELD OF INVENTION
The present invention is based on the combination of the specific compounds and their effects on various diseases.
PRIOR ART
In the existing system as given in US 2007/0010700 Al (patent application) wherein The invention relates to safety containers for biologically active substances, in particular cytostatic agents, said container having increased or higher fracture strength and shatterproof qualities, in addition to an uncontaminated exterior. The invention also relates to a method for producing said containers and to the use of a medium containing at least one polymer for decontaminating the exterior of a container that is filled with a biologically active substance, sealed and optionally labelled.
In the existing system as given in WO 2010/070028 Al (patent application) wherein The present invention relates to a process for producing a solid, coated pharmaceutical composition by a melt coating process. The process is adapted to provide a solid, coated pharmaceutical composition by melt coating, which has a fast release.
In the existing system as given in US 2008/0226684 Al "(patent application) wherein The present invention includes compositions, methods, systems and kits for the controlled delivery of an active agent within a polymeric network upon the binding of a molecule that decreases the structural integrity of the polymeric network at one or more micro- or nanovacuoles.
In the existing system as given in WO 2006/088305 Al (patent application) wherein The present invention relates to a gastric-retentive controlled release mono-matrix tablet composition, comprising: a) at least one pharmacologically active substance; b) hydrogel- forming materials consisting of polyethylene oxide and at least one component selected from
poloxamers and colloidal silica; and c) a carbon dioxide-generating material. The composition of the present invention floats in gastric juice and can continuously release the active substance in the stomach at a constant rate for at least 2 hours.
In the existing system as given in WO 2005/123138 Al (patent application) wherein The present invention provides a pharmaceutical composition in the form of pellet wherein controlled release of pharmacologically active substances can be effected. The present invention is characterized by a pharmaceutical composition for controlled release pellets, consisting es-1 sentially of: a) one or more pharmacologically active substances; b) one or more lipids having a low-melting point of less than 70°C and existing as a solid at room temperature; c) one or more hydrophilic substances; and d) one or more water-insoluble binding agents, prepared without melting the lipids.
In the existing system as given in WO 2008/148798 A2 (patent application)/ AU 2008/258596 Al (patent application)/ US 2010/0239667 Al (patent application) wherein Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof, the solid inner layer being sandwiched between two outer layers Bl) and B2), each outer layer comprising iii) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the form of one of a) a homopolymer having a MW of at least about 100,000 daltons, and b) a copolymer having a MW of at least about 2,000 daltons, or a mixture thereof, and iv) an active substance, which is the same as in said solid inner layer A), and layer A being different from layer B, the layered composition being coated with a coating C) that has at least one opening exposing at least one surface of said outer layer, the coating being substantially insoluble in and impermeable to fluids and comprising a polymer, and the composition having a cylindrical form optionally with one or more tapered ends, wherein the ratio between the surface area of one end surface of the cylinder and the length of the cylinder is in a range of from 0.02 to 45 mm.
In the existing system as given in US 2004/0259809 Al (patent application) wherein the present invention provides pharmaceutical compositions including a sedating antihistamine and a stimulant, and methods of use thereof. The stimulant reduces the sedation caused by the antihistamine, thereby allowing potent, but sedating, antihistamines to be used effectively.
In the existing system as given in WO 2010/029545 A2 (patent application) wherein the present invention relates to novel compounds that are useful for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of infectious diseases. In the existing system as given in United States Patent 61 14344 wherein the subject invention concerns novel compounds that are useful as long-acting local anesthetics. The compounds are N-acyl derivatives of the compound known as tetracaine.
THE OBJECT OF THE INVENTION
An object of the present invention is the provisions of some features distinguish from others. These features are Pain management is qualitatively superior with paracetamol than with other NSAIDs drugs because paracetamol is considered to be the inhibition of cyclooxygenase (COX), and it is highly selective for COX-2.While it has analgesic and antipyretic properties comparable to those of aspirin or other NSAIDs,Pharmacological inhibition of COX can provide relief from the symptoms of inflammation and pain.
The tolerability profile of paracetamol is better than conventional NSAIDs and is similar to that of coxibs (with respect to ulcer incidence) because paracetamol (acetaminophen), owing to its inhibitory action on cyclooxygenase, (sometimes) the paracetamol inhibiting cyclooxygenase predominantly in the central nervous system. There is some speculation that paracetamol acts through the inhibition of the recently discovered COX-3 isoform.
In the case of symptoms of PMS (premenstrual syndrome) like headaches, muscular, joint pain, stomach cramps and sore breasts. Paracetamol may relieve, but they can make fluid retention worse.
The other side effects of NSAIDs for example Ibuprofen, Indomethacin and Diclofenac may cause G.I. irritation and Cardiac Risk with COX2 inhibitor.
STATEMENT OF INVENTION
This invention is mainly focused compounds, efficacy of compounds and combination of compounds. Which essential for treatment of a number of diseases. These are pain, antiinfilamation, hepatoprotective, fever thereof.
DETAILED DESCRIPTION OF THE INVENTION
The present invention discloses an efficient compound, compound combination and additional mechanism of compound which has several mechanisms for treatment of a number of diseases which can be treated from paracetamol, racemethionine, caffeine, chlorpheniramine maleate and Phenylephrine in variable quantities.
Example- Neuroblastomas, pain, hepatoprotective, fever, infilamation, allergy thereof.
Paracetamol
It is a widely used over-the-counter analgesic (pain reliever) and antipyretic (fever reducer). It is commonly used for the relief of headaches, other minor aches and pains, and is a major ingredient in numerous cold and flu remedies. The main mechanism of action of paracetamol is considered to be the inhibition of cyclooxygenase (COX), and recent findings suggest that it is highly selective for COX-2. While it has analgesic and antipyretic properties comparable to those of aspirin or other NSAIDs, its peripheral anti-inflammatory activity is usually limited by several factors, one of which is high level of peroxides present in inflammatory lesions. However, in some circumstances, even peripheral anti-inflammatory activity comparable to other NSAIDs can be observed Because of its selectivity for COX-2 it does not significantly inhibit the production of the pro-clotting thromboxanes.
Mechanism of paracetamol
• Inhibition of platelet activating factor synthesis
• Prevention of Bradykinin/Cytokine induced hyperalgesia of nerves
• Scavenging of hypochlorous acid.
• Blocking of histamine release.
• Prevention of cartilage damage by inhibition of metalloprotease synthesis
• Phosphodiesterase type IV inhibition.
Neuroblastomas
Small tumors of the sympathetic nervous system (neuroblastoma) have abnormal levels of COX-2 expressed.
Cancer
COX-2 appears to be related to cancers and abnormal growths in the intestinal tract. COX inhibitors have been shown to reduce the occurrence of cancers and pre-cancerous growths. The inhibition of COX-2 is paramount for the anti-inflammatory and analgesic function of the selective COX-2 inhibitor celecoxib, and quite likely also for its ability to prevent the development of cancerous growth.
The concentration of paracetamol is 500 mg/tablet and thereof.
Mechanism of action is that makes paracetamol such an effective and useful medicine. Paracetamol has a highly targeted action in blocking an enzyme involved in the transmission of pain.
Racemethionine
It's anti-oxidant nutritional supplement to treat liver diseases caused by alcoholism including cirrhosis. Racemethionine is an important sulphur containing amino acid with multiple functions throughout the body. Its role as an antioxidant and hepatoprotector has been widely documented. It protects hepatocytes and enhances their regeneration thus improving liver function, it acts as important sulphur and methyl group donor in detoxification reactions in liver cells. Methyl group and is essential for many biochemical reactions. Methionine produces S-adenosylmethionine. (SAMe). SAMe is essential for the production of Glutathione. Racemethionine is used to make the urine more acidic. Making the urine more acidic helps to relieve skin irritation in incontinent (loss of bladder control). Racemethionine is necessary for glutathione synthesis. Glutathione plays an important role in
the protection of liver cells. Glutathione (-SH) controls redox reactions and acts as an antioxidant and antitoxic substance.
Methionine neutralizes Hypochlorous acid, a bleach-like substance that is secreted in the painful joints during conditions like rheumatoid arthritis. Thus methionine a lleviates the inflammation that is experienced as pain.Racemethionine has an important antiinflammatory
property which is useful in arthritis and low back pain. It helps in the synthesis of substance t hat helps to keep the gel like cartilage that Cushions joint intact. These properties make race methionine as an important partner with NSAIDs including paracetamol.
The concentration of racemethionine is 50 mg./tablet and thereof. Race Methionine acts as a glutathione precursor. The incorporation of methionine into tablets of paracetamol is useful for protecting against hepatic and renal toxicity.
Glutathione
It's Free Radicals (A molecule which is neutral contains pair of electrons while unpaired molecules are called free radicals.)
Pain and inflammation are caused by the overproduction of free radicals. A free radical called superoxide which is involved in the inflammation of arthritis. Oxidative stress seems to play a vital role in osteoarthritis, in the case of osteoarthritis human cartilage significantly deficient in superoxide dimutase a major free radical scavenger.
Caffeine
Caffeine may also have hepatoprotective properties. Increased caffeine consumption is associated with less severe liver injury among those at high risk for liver disease, such as those with alcoholism, obesity, or hemochromatosis.
Caffeine also increases the effectiveness of some drugs. Many over-the-counter headache drugs include caffeine in their formula. It is also used with ergotamine in the treatment of migraine and cluster headaches as well as to overcome the drowsiness caused by antihistamines.
The concentration of caffeine is 15 mg. /tablet and thereof.
Mechanism of caffeine is that Coffee is- a complex 'blend' of a vast number of different chemicals, any of which may be responsible for its reported effects on the liver.
In addition to the variable quantity of paracetamol and about the equivalent amount of caffeine in a cup of coffee Midol also contains a mild sedative (an antihistamine) and a mild diuretic.
The effects of caffeine are thought to occur as a result of competitive antagonism at adenosine receptors. Adenosine is a water-soluble compound of adenine and ribose; it functions to modulate the activities of nerve cells and produces a mild sedative effect when it activates certain types of adenosine receptors. Caffeine competes with adenosine to bind at these receptors and counteracts the sedative effects of the adenosine. If the person stops drinking coffee, the adenosine has no competition for activating its usual receptors and may produce a sedative effect that is experienced as fatigue or drowsiness.
Chlorpheniramine Maleate
Chlorpheniramine is often combined with phenylpropanolamine to form an allergy medication with both antihistamine and decongestant properties. It's suitable compound for cough and cold .it's containing codeine and chlorpheniramine. It's a first-generation alkylamine antihistamine used in the prevention of the symptoms of allergic conditions. It is also a potentiator of opioids, allowing enhanced suppression of cough, analgesia, and other effects from a given quantity of the drug by itself. In various places in the world, cough and cold preparations containing codeine and chlorpheniramine are available.
The concentration of chlorphenamine maleate is 2 mg/tablet and thereof.
Mechanism of chlorphenamine maleate is that Chlorpheniramine is a histamine HI antagonist (or more correctly, an inverse histamine agonist). It competes with histamine for the normal Hi -receptor sites on effectors cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. It binds to the histamine HI receptor. These blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Absorption well absorbed in the gastrointestinal tract.
Phenylephrine
Phenylephrine's effectiveness as a decongestant stems from its vasoconstriction of nasal blood vessels, thereby decreasing blood flow to the sinusoidal vessels, leading to decreased mucosal edema. All effective cold remedies containing phenylephrine.
The concentration of Phenylephrine is 5 mg/tablet and thereof.
Mechanism of Phenylephrine is that it relieves stuffy nose by constricting blood vessels in the nasal air passages. This reduces the flow of fluid out of the blood vessels and into the tissues of the air passages. Phenylephrine is used to treat runny or stuffy nose, sinus congestion, sneezing, itchy nose, itchy or watery eyes, sore throat, cough, headache, and pain or fever caused by allergies or the common cold.
Claims
1. Synergistic effects of the combination of the specific compounds and their effects on various diseases.
2. Synergistic effects of the combination of the specific compound comprises of paracetamol, racemethionine, caffeine, chlorpheniramine maleate and Phenylephrine in variable quantities.
3. Synergistic effect of the combination of the specific compound is claimed as claim 1 wherein said these are pain, antiinfilamation, hepatoprotective, fever, allergy thereof. This combination has less toxicity, it has not hepatotoxicity property.
4. Synergistic effects of the combination of the specific compound are claimed as claim 2 wherein said the mechanism of paracetamol is that inhibition of cyclooxygenase (COX), and recent findings suggest that it is highly selective for COX-2. It's selectivity for COX-2 it does not significantly inhibit the production of the pro- clotting thromboxanes. The concentration of paracetamol is 500mg and thereof.
5. Synergistic effects of the combination of the specific compound is claimed as claim 2 wherein said Racemethionine is anti-oxidant nutritional supplement to treat liver diseases caused by alcoholism including cirrhosis. It protects hepatocytes and enhances their regeneration thus improving liver function. It acts as important sulphur and methyl group donor in detoxification reactions in liver cells. It protects hepatocytes and enhances their regeneration thus improving liver function. The concentration of racemethionine is 50mg and thereof.
6. Synergistic effects of the combination of the specific compound are claimed as claim 2 wherein said all effective cold remedies containing phenylephrine. The concentration of Phenylephrine is 5 mg/tablet and thereof. Phenylephrine to form an allergy medication with both antihistamine and decongestant properties.
7. Synergistic effects of the combination of the specific compound is claimed as claim 2 wherein said Chlorphenaminemaleate is suitable compound for cough and cold .chlorphenamine maleate to form an allergy medication with both antihistamine and decongestant properties. The concentration of chlorphenaminemaleate is 2 mg./tablet and thereof.
8. Synergistic effects of the combination of the specific compound are claimed as claim 2 wherein said Caffeine may also have hepatoprotective properties. Increased caffeine
1 consumption is associated with less severe liver injury among those at high risk for liver disease, such as those with alcoholism, obesity, or hemochromatosis. The Concentration of caffeine is 15 mgVtablet and thereof.
9. Synergistic effects of the combination of the specific compound are claimed as claim 5 wherein said Race Methionine acts as a glutathione precursor. The incorporation of methionine into tablets of paracetamol is useful for protecting against hepatic and renal toxicity.
10. Synergistic effects of the combination of the specific compound are claimed as claim 8 wherein said In addition to the variable quantity of paracetamol and about the equivalent amount of caffeine in a cup of coffee Midol also contains a mild sedative (an antihistamine) and a mild diuretic.
2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3568/MUM/2010 | 2010-12-30 | ||
| IN3568MU2010 | 2010-12-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012090218A1 true WO2012090218A1 (en) | 2012-07-05 |
| WO2012090218A4 WO2012090218A4 (en) | 2012-08-23 |
Family
ID=45607327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2011/000867 WO2012090218A1 (en) | 2010-12-30 | 2011-12-19 | Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012090218A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013211546B1 (en) * | 2013-02-04 | 2013-12-19 | Aft Pharmaceuticals Limited | A Medicament |
| EP2830605A4 (en) * | 2013-02-04 | 2015-02-04 | Aft Pharmaceuticals Ltd | DRUG COMBINATION COMPRISING PHENYLEPHRINE AND PARACETAMOL |
| CN108186579A (en) * | 2018-02-01 | 2018-06-22 | 重庆希尔安药业有限公司 | Xiao ' er Anfen Huangnamin composition grain and preparation method thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6114344A (en) | 1998-07-16 | 2000-09-05 | Aryx Therapeutics | Long-acting local anesthetics |
| US20040259809A1 (en) | 2003-06-17 | 2004-12-23 | Pediamed Pharmaceuticals, Inc. | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof |
| WO2005097120A1 (en) * | 2004-03-31 | 2005-10-20 | Winston Laboratories, Inc. | Compositions with reduced hepatotoxicity |
| WO2005123138A1 (en) | 2004-03-17 | 2005-12-29 | Chong Kun Dang Pharmaceutical Corp. | Pharmaceutical pellet compositions for controlled release |
| WO2006088305A1 (en) | 2005-02-15 | 2006-08-24 | Chong Kun Dang Pharmaceutical Corp. | Gastric-retentive controlled release mono-matrix tablet |
| US20070010700A1 (en) | 2001-01-09 | 2007-01-11 | Baxter International Inc | Safety containers for biologically active substances and method for producing said container |
| US20080226684A1 (en) | 2007-03-12 | 2008-09-18 | Board Of Regents, The University Of Texas System | Method and process for the production of multi-coated recognitive and releasing systems |
| WO2008148798A2 (en) | 2007-06-04 | 2008-12-11 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| WO2010029545A2 (en) | 2008-09-11 | 2010-03-18 | Ben Gurion University Of The Negev Research And Development Authority | Compositions and methods for treating s. pneumoniae infection |
| WO2010070028A1 (en) | 2008-12-17 | 2010-06-24 | Losan Pharma Gmbh | Melt-coated pharmaceutical composition with fast release |
-
2011
- 2011-12-19 WO PCT/IN2011/000867 patent/WO2012090218A1/en active Application Filing
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6114344A (en) | 1998-07-16 | 2000-09-05 | Aryx Therapeutics | Long-acting local anesthetics |
| US20070010700A1 (en) | 2001-01-09 | 2007-01-11 | Baxter International Inc | Safety containers for biologically active substances and method for producing said container |
| US20040259809A1 (en) | 2003-06-17 | 2004-12-23 | Pediamed Pharmaceuticals, Inc. | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof |
| WO2005123138A1 (en) | 2004-03-17 | 2005-12-29 | Chong Kun Dang Pharmaceutical Corp. | Pharmaceutical pellet compositions for controlled release |
| WO2005097120A1 (en) * | 2004-03-31 | 2005-10-20 | Winston Laboratories, Inc. | Compositions with reduced hepatotoxicity |
| WO2006088305A1 (en) | 2005-02-15 | 2006-08-24 | Chong Kun Dang Pharmaceutical Corp. | Gastric-retentive controlled release mono-matrix tablet |
| US20080226684A1 (en) | 2007-03-12 | 2008-09-18 | Board Of Regents, The University Of Texas System | Method and process for the production of multi-coated recognitive and releasing systems |
| WO2008148798A2 (en) | 2007-06-04 | 2008-12-11 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| AU2008258596A1 (en) | 2007-06-04 | 2008-12-11 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| US20100239667A1 (en) | 2007-06-04 | 2010-09-23 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| WO2010029545A2 (en) | 2008-09-11 | 2010-03-18 | Ben Gurion University Of The Negev Research And Development Authority | Compositions and methods for treating s. pneumoniae infection |
| WO2010070028A1 (en) | 2008-12-17 | 2010-06-24 | Losan Pharma Gmbh | Melt-coated pharmaceutical composition with fast release |
Non-Patent Citations (6)
| Title |
|---|
| "Should methionine be added to paracetamol formulations?", DRUGS AND THERAPY PERSPECTIVES 19971124 NZ, vol. 10, no. 11, 24 November 1997 (1997-11-24), pages 11 - 13, XP009158126, ISSN: 1172-0360 * |
| ANONYMOUS: "Hycomine Compound Tablets (Endo Labs)", DRUG REFERENCE ENCYCLOPEDIA, 1 May 2003 (2003-05-01), pages 1 - 6, XP055023757, Retrieved from the Internet <URL:http://www.theodora.com/drugs/hycomine_compound_tablets_endo_labs.html> [retrieved on 20120403] * |
| ANONYMOUS: "Matched Brand/Brands of Paracetamol,Chlorpheniramine Maleate,Phenylephrine,Caffeine", MEDGUIDEINDIA.COM, 1 January 2010 (2010-01-01), pages 1 - 3, XP055023756, Retrieved from the Internet <URL:http://www.medguideindia.com/find_brand_bygeneric.php?gen_mask=,2,31,73,271,> [retrieved on 20120403] * |
| CHAN T Y K ET AL: "Metabolic activation and paracetamol hepatotoxicity - An update on the management of paracetamol (acetaminophen) poisoning", JOURNAL OF THE HONG KONG MEDICAL ASSOCIATION 1994 HK, vol. 46, no. 1, 1994, pages 87 - 92, XP009158117, ISSN: 1010-8424 * |
| DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 2001, KANUMULA GANGARAM V ET AL: "Concurrent analysis of a multicomponent dosage formulation containing chlorpheniramine maleate, phenylephrine HCl, caffeine and acetaminophen by RP-HPLC with wavelength programming", XP002673506, Database accession no. EMB-2001277173 * |
| DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; March 2004 (2004-03-01), DI GIROLAMO G ET AL: "Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea?", XP002673508, Database accession no. EMB-2004125392 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013211546B1 (en) * | 2013-02-04 | 2013-12-19 | Aft Pharmaceuticals Limited | A Medicament |
| EP2830605A4 (en) * | 2013-02-04 | 2015-02-04 | Aft Pharmaceuticals Ltd | DRUG COMBINATION COMPRISING PHENYLEPHRINE AND PARACETAMOL |
| CN108186579A (en) * | 2018-02-01 | 2018-06-22 | 重庆希尔安药业有限公司 | Xiao ' er Anfen Huangnamin composition grain and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012090218A4 (en) | 2012-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6139743B2 (en) | Loxoprofen-containing pharmaceutical composition | |
| DK1992333T3 (en) | Flurbiprofen and muscle relaxant combinations | |
| WO2014020155A1 (en) | Oral transmucosal adminstration forms of s-ketamine | |
| JP4489289B2 (en) | Method for treating an anal pain condition and composition therefor | |
| JP5897804B2 (en) | Loxoprofen-containing pharmaceutical composition | |
| WO2016100543A2 (en) | Hypochlorous acid formulations and methods for treating skin conditions | |
| CA2671490A1 (en) | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity | |
| JP5952944B2 (en) | Loxoprofen or a pharmaceutical composition containing a salt thereof II | |
| WO2021177940A1 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
| CA2403994C (en) | Nasal administration of agents for the treatment of gastroparesis | |
| WO2012090218A1 (en) | Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases | |
| WO2009123206A1 (en) | Oral pharmaceutical composition | |
| CA2476939A1 (en) | Pharmaceutical combinations of cox-2 inhibitors and opiates | |
| US20140163105A1 (en) | Topical preparation for pain relief | |
| CN101278933A (en) | Medicament composition containing dimemorfan and method of preparing the same | |
| US11229610B2 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
| WO2015157729A1 (en) | Pharmaceutical formulations an comprising analgesic agent, a nonsteroidal anti-inflammatory agent, a gastric acid production suppressant and an anti-nauseant | |
| US9867789B2 (en) | Non-steroidal anti-inflammatory drugs for cough | |
| RU2006139819A (en) | APPLICATION OF SYMETICON FOR PATIENTS POSITIONED FOR CONSTIPATION | |
| US20200108025A1 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
| AU2002307872B2 (en) | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine for the treatment of pain | |
| CN102210681B (en) | Application of ectoine and derivatives thereof in preparing medicament for treating digestive tract diseases | |
| US20220193091A1 (en) | Combined administration of diazepam and diclofenac for the treatment of pain | |
| US20150342989A1 (en) | Compositions comprising non steroidal anti-inflammatory drugs and methods of use thereof | |
| JP2009007338A (en) | Suppository formulation composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11817542 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11817542 Country of ref document: EP Kind code of ref document: A1 |